open access

Online first
Clinical vignette
Published online: 2022-06-15
Get Citation

Effective cardioprotection with early initiation of sacubitril-valsartan in a patient with breast cancer and cancer treatment-induced heart failure

Grzegorz Sławiński1, Hanna Jankowska2, Aleksandra Liżewska-Springer1, Ewa Lewicka1
DOI: 10.33963/KP.a2022.0145
·
Pubmed: 35703431
Affiliations
  1. Department of Cardiology and Electrotherapy, Medical University of Gdansk, Gdańsk, Poland
  2. Department of Noninvasive Cardiac Diagnostics, Medical University of Gdansk, Gdańsk, Poland

open access

Online first
Clinical vignette
Published online: 2022-06-15

Abstract

Not available

Abstract

Not available
Get Citation
Supp./Additional Files (7)
Supplementary material. Panel-A-2CH-view
Download
2MB
Supplementary material. Panel-A-4CH-view
Download
2MB
Supplementary material. Panel-B-2CH-view
Download
756KB
Supplementary material. Panel-B-4CH-view
Download
764KB
Supplementary material. Panel-C-2CH-view
Download
1MB
Supplementary material. Panel-C-4CH-view
Download
2MB
Supplementary material
Download
61KB
About this article
Title

Effective cardioprotection with early initiation of sacubitril-valsartan in a patient with breast cancer and cancer treatment-induced heart failure

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Clinical vignette

Published online

2022-06-15

Page views

163

Article views/downloads

116

DOI

10.33963/KP.a2022.0145

Pubmed

35703431

Authors

Grzegorz Sławiński
Hanna Jankowska
Aleksandra Liżewska-Springer
Ewa Lewicka

References (5)
  1. Cho H, Lee S, Sim SH, et al. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients. Breast Cancer Res Treat. 2020; 182(2): 333–343.
  2. Słowik A, Jagielski P, Potocki P, et al. Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study. Kardiol Pol. 2020; 78(2): 131–137.
  3. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
  4. Xi Q, Chen Z, Li T, et al. Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction. J Int Med Res. 2022; 50(1): 3000605211067909.
  5. Martín-Garcia A, López-Fernández T, Mitroi C, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail. 2020; 7(2): 763–767.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl